Study Examines Diabetes Medications and Lung Inflammation Risk in Cancer Immunotherapy Patients
Researchers utilizing a Japanese claims database investigated whether baseline glucose-lowering drugs affect the risk of immune checkpoint inhibitor-induced pneumonitis in type 2 diabetes patients.
Key points
- Retrospective cohort study analyzed 21,738 cancer patients with type 2 diabetes.
- Primary analysis found no clear link between baseline glucose-lowering drugs and pneumonitis.
- Concomitant immunotherapy and younger age showed varied associations with the lung complication risk.
A recent retrospective cohort study published in Scientific Reports has explored whether baseline glucose-lowering treatments are linked to the development of immune checkpoint inhibitor-induced pneumonitis among cancer patients with type 2 diabetes. Led by researchers including Yoko Kobayashi and Takeshi Horii from Musashino University and Kitasato University in Japan, the investigation analyzed data from a large-scale claims database covering the period from April 2014 to October 2023.
Study Findings and Key Observations
The study reviewed 21,738 eligible patients newly starting immune checkpoint inhibitor-based chemotherapy. Out of this cohort, 1,164 individuals, representing 5.4 percent, experienced immune-related pneumonitis. In the primary multivariable logistic regression analysis, no specific class of glucose-lowering medication taken at the start of immunotherapy showed a statistically significant link to the lung complication. For instance, the adjusted odds ratio for DPP-4 inhibitors stood at 0.89.
- Concomitant use of immune checkpoint inhibitors was associated with increased odds of developing pneumonitis, showing an odds ratio of 1.40.
- Older age demonstrated an inverse association, with lower odds observed per 10-year increase in age (odds ratio of 0.82).
- A sensitivity analysis focusing on cases requiring hospitalization suggested potential associations with certain drug classes like SGLT2 inhibitors and insulin, though authors noted these required careful interpretation due to fewer events.
What to know: Baseline use of diabetes medications did not demonstrate a clear protective or harmful association with immunotherapy-induced lung inflammation in the primary analysis. Readers are encouraged to consult a qualified healthcare provider for personal medical decisions and treatment management.
Source Nature Health Sciences — nature.com/articles/s41598-026-80275-w ↗
Read next
🧠Mind & Mental HealthAddressing Body Image and the Reality of Gluteal Anatomy
A personal reflection on the social and psychological impact of body shape, specifically regarding the gluteal region, and the limitations of consumer solutions for perce…
❤️Conditions & CareMigraine and Smoking Linked to Increased Early Stroke Risk in Women
A large-scale study suggests that people who have given birth and experience migraines while also smoking face a significantly higher risk of stroke before age 60.
🔬ResearchCBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities
A double-blind clinical trial published in JAMA Pediatrics indicates that CBD oil provides no significant behavioral improvement for children and teenagers with intellect…
🏃FitnessExpert Advice on Hydration Gear Sparks Debate Among Recreational Runners
Olympic medalist Josh Kerr recently suggested that runners may not require hydration packs for distances under 12 miles, igniting a broader conversation about gear necess…
🏃FitnessA Structured Approach to Beginning a Strength and Cardio Routine
A new four-week training program offers beginners a guided path to incorporating strength training and cardiovascular exercise into their daily lives.
🧠Mind & Mental HealthThe Role of Daily Mobility Training in Managing Sedentary Tension
A two-week personal trial suggests that incorporating short, daily mobility exercises may help alleviate stiffness associated with sedentary desk work. Experts note that …